Merck Press Releases

Published on February 3, 2014 - 14:16 GMT

Merck Announces Canadian Approval of GRASTEK® (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the regulatory approval and launch of GRASTEK® (Timothy grass pollen allergen extract) sublingual tablets in Canada. This …

Distribution channels: Companies

Published on February 3, 2014 - 14:04 GMT

Merck Announces Canadian Approval of GRASTEK® (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the regulatory approval and launch of GRASTEK® (Timothy grass pollen allergen extract) sublingual tablets in Canada. This …

Distribution channels: Companies

Published on January 29, 2014 - 03:40 GMT

Merck Statement on FDA Advisory Committee Meeting for RAGWITEK™ (Short Ragweed Pollen Allergen Extract), an Investigational ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said it was pleased with the positive discussion of RAGWITEK™ (Short Ragweed Pollen Allergen Extract) at the Allergenic Products Advisory Committee meeting of the U.S. Food and …

Distribution channels: Companies

Published on January 29, 2014 - 03:29 GMT

Merck Statement on FDA Advisory Committee Meeting for RAGWITEK™ (Short Ragweed Pollen Allergen Extract), an Investigational ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said it was pleased with the positive discussion of RAGWITEK™ (Short Ragweed Pollen Allergen Extract) at the Allergenic Products Advisory Committee meeting of the U.S. Food and …

Distribution channels: Companies

Published on January 16, 2014 - 00:34 GMT

Merck Statement on FDA Advisory Committee for Vorapaxar, Merck’s Investigational Antiplatelet Medicine

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said it was pleased with the U.S. Food and Drug Administration (FDA)’s Cardiovascular and Renal Drugs Advisory Committee’s recommendation …

Distribution channels: Companies

Published on January 16, 2014 - 00:32 GMT

Merck Statement on FDA Advisory Committee for Vorapaxar, Merck’s Investigational Antiplatelet Medicine

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said it was pleased with the U.S. Food and Drug Administration (FDA)’s Cardiovascular and Renal Drugs Advisory Committee’s recommendation …

Distribution channels: Companies

Published on January 13, 2014 - 13:42 GMT

Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today it has started a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application for MK-3475 …

Distribution channels: Companies

Published on January 13, 2014 - 13:42 GMT

Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today will report on the strategic and operating actions it is taking to drive short- and long-term growth, including sharpening its focus in …

Distribution channels: Companies

Published on January 13, 2014 - 13:42 GMT

Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today it has started a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application for MK-3475 …

Distribution channels: Companies

Published on January 10, 2014 - 14:14 GMT

Merck to Present at the 32nd Annual J.P. Morgan Healthcare Conference

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, Merck's chairman and chief executive officer, is scheduled to present at the 32ndAnnual J.P. Morgan …

Distribution channels: Companies

Published on January 8, 2014 - 14:01 GMT

Merck Receives FDA Approval for ISENTRESS® (raltegravir) for Pediatric Oral Suspension

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) recently approved ISENTRESS® for oral suspension, a new pediatric formulation …

Distribution channels: Companies

Published on January 6, 2014 - 22:24 GMT

Merck to Hold Fourth-Quarter 2013 Sales and Earnings Conference Call on February 5

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter 2013 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Wednesday, …

Distribution channels: Companies

Published on December 20, 2013 - 14:02 GMT

Merck Announces Launch of a New Business Focused on Comprehensive, Evidence-Based Weight Management Interventions in the U.S.

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of a new business focused on providing comprehensive, evidence-based weight management interventions for employers, …

Distribution channels: Companies

Published on December 18, 2013 - 13:04 GMT

Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the company’s investigational anti-PD-1 immunotherapy, MK-3475 …

Distribution channels: Companies

Published on December 18, 2013 - 12:57 GMT

Merck Collaborates with GlaxoSmithKline to Evaluate Novel Combination Regimen for Advanced Renal Cell Carcinoma

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the initiation of a clinical trial to evaluate the combination of the company’s investigational anti-PD-1 immunotherapy, MK-3475 …

Distribution channels: Companies

Published on December 17, 2013 - 10:06 GMT

MSD Animal Health Receives Positive Opinion from European Medicines Agency for BRAVECTO™ (fluralaner)

SUMMIT, N.J.--(BUSINESS WIRE)--MSD Animal Health (known as Merck Animal Health in the United States and Canada) today announced that the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency has adopted a positive …

Distribution channels: Companies

Published on December 13, 2013 - 00:37 GMT

Merck Statement on FDA Advisory Committee for GRASTEK® (Timothy Grass Pollen Allergen Extract), Merck’s Investigational Sublingual ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of the Allergenic Products Advisory Committee of the U.S. Food and Drug Administration …

Distribution channels: Companies

Published on December 10, 2013 - 12:28 GMT

Merck Advances Development Program for Investigational Alzheimer’s Disease Therapy, MK-8931

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the development program for MK-8931, a novel investigational oral β-amyloid precursor protein site-cleaving enzyme ( …

Distribution channels: Companies

Published on November 26, 2013 - 21:19 GMT

FDA Approves Merck’s NOXAFIL® (posaconazole) Delayed-Release Tablets

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets. NOXAFIL …

Distribution channels: Companies

Published on November 26, 2013 - 21:18 GMT

FDA Approves Merck’s NOXAFIL® (posaconazole) Delayed-Release Tablets

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets. NOXAFIL …

Distribution channels: Companies

Merck Press Releases Distributed by EIN Presswire